Should I target ApoB below 60 mg/dL?

Aggressive ApoB targets reduce events; the precise <60 threshold is extrapolation beyond current guidelines.

Our read is Partially Supported. The core mechanism holds and the direction is right, but the popular framing tends to overrun what the trials actually show. With a developing evidence base (62/100) and a working majority (64% consensus), targeting ApoB below 60 mg/dL is reasonable for the right person at $15/month — just calibrate the expectation to the data, not the marketing.

Pulled the public claims about targeting ApoB below 60 mg/dL from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.

• 01Expert consensus: 64% — a working majority among the voices we track.
• 02Evidence strength: 62/100, which we read as a developing evidence base.
• 03Direction of effect: real, but smaller than the popular framing of targeting ApoB below 60 mg/dL implies.
• 04Best-supported slice: a specific population or protocol carries most of the signal; generalizing past it is where claims fray.
• 05Weakest link: long-term and hard-outcome data lag the mechanistic and short-term findings.

This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so targeting ApoB below 60 mg/dL is not a casual decision. Loop in a clinician who can see your full history before starting.

A large, long-duration RCT in a general population that either confirms a hard-outcome benefit or shows the effect washes out once it is properly controlled.